Abstract
There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 538-545 |
| Number of pages | 8 |
| Journal | Advances in Wound Care |
| Volume | 8 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2019 |
Fingerprint
Keywords
- absorption
- adrenergic receptor
- catecholamine
- chronic wounds
- glaucoma
- timolol
ASJC Scopus subject areas
- Emergency Medicine
- Critical Care and Intensive Care Medicine
Cite this
Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. / Gallegos, Anthony Cole; Davis, Michael James; Tchanque-Fossuo, Catherine N.; West, Kaitlyn; Eisentrout-Melton, Angela; Peavy, Thomas R.; Dixon, Roy W.; Patel, Roma P.; Dahle, Sara Evona; Isseroff, Roslyn Rivkah.
In: Advances in Wound Care, Vol. 8, No. 11, 01.11.2019, p. 538-545.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds
AU - Gallegos, Anthony Cole
AU - Davis, Michael James
AU - Tchanque-Fossuo, Catherine N.
AU - West, Kaitlyn
AU - Eisentrout-Melton, Angela
AU - Peavy, Thomas R.
AU - Dixon, Roy W.
AU - Patel, Roma P.
AU - Dahle, Sara Evona
AU - Isseroff, Roslyn Rivkah
PY - 2019/11/1
Y1 - 2019/11/1
N2 - There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.
AB - There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.
KW - absorption
KW - adrenergic receptor
KW - catecholamine
KW - chronic wounds
KW - glaucoma
KW - timolol
UR - http://www.scopus.com/inward/record.url?scp=85073879406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073879406&partnerID=8YFLogxK
U2 - 10.1089/wound.2019.0970
DO - 10.1089/wound.2019.0970
M3 - Article
AN - SCOPUS:85073879406
VL - 8
SP - 538
EP - 545
JO - Advances in Wound Care
JF - Advances in Wound Care
SN - 2162-1918
IS - 11
ER -